BACKGROUND: Brachytherapy (BT) is an established treatment option for low risk prostate cancer. The aim of this study was to determine the long-term complications and side effects of the procedure in an up to 13 year long single center follow-up analysis. MATERIAL: A total of 505 patients were treated by BT for prostate cancer between May 1991 and August 2005. Cohort I (n=412; May 1991 to November 2003) was evaluated by written questionnaire (modified ICS male) and patient chart evaluation in terms of side effects and secondary interventions. In cohort II (n=148; January 2002 to August 2005) perioperative complications were investigated. RESULTS: The mean follow-up was 5.5 years. Perioperative complications were present in 5.4% of patients. Transurethral resection of the prostate was a common secondary intervention, performed in 7% of cases. The rate of incontinence was 6.3% in the long-term follow-up, the rate of potency was 43.5% in those patients who were potent before BT and no hormonal manipulation was performed at any time. CONCLUSION: BT is a minimally invasive procedure for the treatment of localised "low risk" prostate cancer. Perioperative complications are rare, secondary intervention may be necessary and the patient has to be informed of possible impotence, incontinence and lack of ejaculation.
BACKGROUND: Brachytherapy (BT) is an established treatment option for low risk prostate cancer. The aim of this study was to determine the long-term complications and side effects of the procedure in an up to 13 year long single center follow-up analysis. MATERIAL: A total of 505 patients were treated by BT for prostate cancer between May 1991 and August 2005. Cohort I (n=412; May 1991 to November 2003) was evaluated by written questionnaire (modified ICS male) and patient chart evaluation in terms of side effects and secondary interventions. In cohort II (n=148; January 2002 to August 2005) perioperative complications were investigated. RESULTS: The mean follow-up was 5.5 years. Perioperative complications were present in 5.4% of patients. Transurethral resection of the prostate was a common secondary intervention, performed in 7% of cases. The rate of incontinence was 6.3% in the long-term follow-up, the rate of potency was 43.5% in those patients who were potent before BT and no hormonal manipulation was performed at any time. CONCLUSION: BT is a minimally invasive procedure for the treatment of localised "low risk" prostate cancer. Perioperative complications are rare, secondary intervention may be necessary and the patient has to be informed of possible impotence, incontinence and lack of ejaculation.
Authors: M P Wirth; T Herrmann; P Alken; G Kovacs; H Müller; O W Hakenberg; L Ahlemann; K Schalkhäuser Journal: Urologe A Date: 2002-07 Impact factor: 0.639
Authors: S K Kang; R H Chou; R K Dodge; R W Clough; H L Kang; M G Bowen; B A Steffey; S K Das; S M Zhou; A W Whitehurst; N J Buckley; J H Kim; R E Joyner; I Sarmina; G S Montana; S S Ingram; M S Anscher Journal: Int J Radiat Oncol Biol Phys Date: 2001-07-15 Impact factor: 7.038
Authors: Gregory S Merrick; Wayne M Butler; Robert W Galbreath; Robin L Stipetich; Laurie J Abel; Jonathan H Lief Journal: Int J Radiat Oncol Biol Phys Date: 2002-03-15 Impact factor: 7.038
Authors: Peter Wust; Daniel Wischka von Borczyskowski; Thomas Henkel; Christian Rosner; Reinhold Graf; Wolfgang Tilly; Volker Budach; Roland Felix; Frank Kahmann Journal: Radiother Oncol Date: 2004-10 Impact factor: 6.280
Authors: Marcos Os Coelho; Luciana Sb Dal Col; Diego M Capibaribe; Carla M Salgado; Thiago C Travassos; Vanderlei J Junior; Carlos R Monti; Leonardo O Reis Journal: Am J Clin Exp Urol Date: 2022-02-15